Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
S0424 - Carcinogens in Lung Tissue From Smokers (Closed to Entry as of 7/15/07) and Non-Smokers With Newly Diagnosed Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer
NCT00450281 · View on ClinicalTrials.gov ↗
Study Summary
RATIONALE: Studying samples of blood and tissue from smokers (closed to entry as of 7/15/07) and non-smokers with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors learn more about risk factors for lung cancer and may help the study of cancer in the future. PURPOSE: This clinical trial is studying carcinogens in lung tissue from smokers (closed to entry as of 7/15/07) and non-smokers with newly diagnosed stage I, stage II, or stage III non-small cell lung cancer.
Conditions Studied
Interventions
- GENETIC gene expression analysis
- GENETIC mutation analysis
- GENETIC polymerase chain reaction
- GENETIC polymorphism analysis
- GENETIC chromogenic in situ hybridization
Study Locations (20)
California
- Kaiser Permanente - Deer Valley — Antioch
- Roy and Patricia Disney Family Cancer Center at Providence Saint Joseph Medical Center — Burbank
- Cancer Care Center at John Muir Health - Concord Campus — Concord
- North Bay Cancer Center — Fairfield
- Kaiser Permanente - Fremont — Fremont
- Glendale Memorial Hospital Comprehensive Cancer Center — Glendale
- Kaiser Permanente Medical Center - Hayward — Hayward
- Tibotec Therapeutics - Division of Ortho Biotech Products, LP — Marysville
- Kaiser Permanente Medical Center - Oakland — Oakland
- Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center — Orange
- Valley Care Medical Center — Pleasanton
- Robert and Beverly Lewis Family Cancer Care Center at Pomona Valley Hospital Medical Center — Pomona
- Kaiser Permanente Medical Center - Redwood City — Redwood City
- Kaiser Permanente Medical Center - Richmond — Richmond
- Kaiser Permanente Medical Center - Roseville — Roseville
- University of California Davis Cancer Center — Sacramento
- Mercy General Hospital — Sacramento
Alaska
- Providence Cancer Center — Anchorage
Arizona
- Arizona Cancer Center at University of Arizona Health Sciences Center — Tucson
Arkansas
- Hembree Mercy Cancer Center at St. Edward Mercy Medical Center — Fort Smith
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 981 participants |
| Start Date | 2005-10 |
| Est. Completion | 2012-07 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00450281
The ClinicalTrials.gov registry entry for NCT00450281 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 981 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 212 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 5 interventions — of which gene expression analysis is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT00450281 reports 20 study locations spanning 4 distinct geographic areas — top geographies include California, Alaska, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT00450281 about?
NCT00450281 is a clinical study titled "S0424 - Carcinogens in Lung Tissue From Smokers (Closed to Entry as of 7/15/07) and Non-Smokers With Newly Diagnosed Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer". RATIONALE: Studying samples of blood and tissue from smokers (closed to entry as of 7/15/07) and non-smokers with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors learn more about risk factors for...
What is the current status of trial NCT00450281?
This trial is currently completed. The enrollment target is 981 participants. The study started on 2005-10. Estimated completion is 2012-07.
What conditions does trial NCT00450281 study?
This clinical trial studies the following conditions: Lung Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT00450281?
The interventions under investigation include: gene expression analysis (GENETIC), mutation analysis (GENETIC), polymerase chain reaction (GENETIC), polymorphism analysis (GENETIC), chromogenic in situ hybridization (GENETIC). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT00450281?
This trial is sponsored by SWOG Cancer Research Network, which has 212 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT00450281 being conducted?
This trial has 20 study locations across Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.